Pfizer-BioNTech announced on Tuesday they have begun late-stage clinical trials of their coronavirus vaccine in children ages five to 11
Lower doses will be used for kids, 10 micrograms, compared to the 30 micrograms that those ages 12 and above receive
The company says it is hoping for data in the latter half of 2021, and is still in the early stages for trials in children between six months to four years old
On Monday, Moderna CEO Stéphane Bancel said he believes his company’s vaccine will be available for kids as young as five years old by early fall
Parents and doctors have been debating about whether or not to inoculate children because they make up just 0.1% of all COVID deaths
ClinicalTrials.gov
Browse the articles related to this topic below.
Join our community on Guilded.
Brief Summary:The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.
| Actual Study Start Date : | August 28, 2020 |
| Actual Primary Completion Date : | March 5, 2021 |
| Estimated Study Completion Date : | February 14, 2023 |
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of mRNA-1273 to prevent COVID-19 for up to 2 years after the second dose of mRNA-1273.
| Actual Study Start Date : | July 27, 2020 |
| Estimated Primary Completion Date : | October 27, 2022 |
| Estimated Study Completion Date : | October 27, 2022 |
For a commentary on this trial, please see the video embedded below.
This study tests different messages about vaccinating against COVID-19 once the vaccine becomes available. Participants are randomized to 1 of 12 arms, with one control arm and one baseline arm. We will compare the reported willingness to get a COVID-19 vaccine at 3 and 6 months of it becoming available between the 10 intervention arms to the 2 control arms.
https://clinicaltrials.gov/ct2/show/NCT04460703
Commentary by Dave Cullen.
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.
| Actual Study Start Date : | April 29, 2020 |
| Estimated Primary Completion Date : | October 29, 2021 |
| Estimated Study Completion Date : | April 6, 2023 |